CalciMedica, Inc. (NASDAQ:CALC) Short Interest Up 309.4% in June

CalciMedica, Inc. (NASDAQ:CALC) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 69,600 shares, a growth of 309.4% from the June 15th total of 17,000 shares. Based on an average trading volume of 35,600 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.6% of the company’s stock are sold short.

CalciMedica Stock Performance

CALC stock opened at $4.72 on Friday. CalciMedica has a one year low of $1.75 and a one year high of $8.38. The company has a fifty day moving average of $5.08 and a 200-day moving average of $4.68.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07. As a group, equities analysts anticipate that CalciMedica will post -2.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CALC. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of CalciMedica in a report on Tuesday. Singular Research raised CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th. Finally, Oppenheimer lifted their target price on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday.

Insider Transactions at CalciMedica

In related news, Director Robert N. Wilson bought 8,443 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average cost of $3.23 per share, with a total value of $27,270.89. Following the purchase, the director now directly owns 258,918 shares of the company’s stock, valued at approximately $836,305.14. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 53.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Meritage Portfolio Management grew its stake in CalciMedica by 360.0% in the 4th quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock valued at $132,000 after acquiring an additional 36,000 shares during the last quarter. BML Capital Management LLC lifted its holdings in shares of CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after purchasing an additional 56,643 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of CalciMedica in the third quarter valued at approximately $432,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.